

Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors

Last Update: Apr 16, 2025

HU-F-AIM - A Prospective, Interventional Study to Evaluate HU-resistance in Polycythemia Vera Patients Who Meet Predictive Parameters Identified in the Machine Learning Project PV-AIM

ClinicalTrials.gov Identifier:

[NCT05853458](#)

Novartis Reference Number:CINC424BDE15

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The purpose of this study is to confirm the predictive factors for hydroxyurea (HU) failure (hemoglobin (HGB) <15.5 g/dL (9.62 mmol/L) and red blood cell distribution width (RDW) $\geq 17\%$) identified by machine learning in the polycythemia vera advanced integrated model (PV-AIM) project in the real-life setting. The study consists of three periods: Screening period, treatment period (observation for HU-resistance/intolerance) and follow-up (FU) period.

Eligible participants will enter the treatment period (observation period for HU-resistance/intolerance) and start receiving the de novo HU treatment. The maximum treatment duration for each participant in the study will be up to 15 months.

This study will be conducted in a total of 300 adult PV patients and approximately at 30 to 40 sites in Germany. If necessary, the study will be extended to other countries to achieve the target population.

Condition

Polycythemia Vera

Phase

Phase4

Overall Status

Recruiting

Number of Participants

300

Start Date

Jul 28, 2023

Completion Date

Jan 27, 2027

Gender

All

Age(s)

Interventions

Drug

Hydroxyurea

Hydroxyurea is commercially available in Germany and will be prescribed based on clinical judgment

Eligibility Criteria

Key Inclusion criteria

1. Signed informed consent must be obtained prior to participation in the study
2. Patients ≥ 18 years
3. Confirmed diagnosis of Polycythemia vera (according to WHO 2008, 2016, or 2022 criteria) (Tefferi and Vardiman 2008, Arber et al 2016, Khoury et al 2022)
4. Eastern Cooperative Oncology Group (ECOG) ≤ 2
5. No previous pharmacologic cytoreductive therapy (including investigational drugs)
6. No phlebotomy in last 14 days
7. HU-eligible

* High-risk: age ≥ 60 years and/or prior history of thrombosis

* Low-risk: showing at least one of the defined criteria

* Signs of disease progression (myeloproliferation):

* Increase in spleen size or symptomatic splenomegaly

* Platelet increase to $> 1,000,000/\mu\text{l}$

* WBC increase to $> 15,000/\mu\text{l}$ or higher

* Frequent (> 10 per year) or increasing frequency of phlebotomies

* Increasing risk of thromboembolism and bleeding:

* New thromboembolism and/or hemorrhagic complications

* Microcirculation disorders despite acetyl salicylic acid (ASA) 2x 100 mg/day

* Restricted feasibility or intolerance of phlebotomies

* Symptomatic iron deficiency

* Uncontrolled increase in hematocrit

* Severe or distressing disease-related symptoms

8. Female participants of childbearing potential should have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study treatment.

Key Exclusion criteria

1. Patients with post-polycythemia vera myelofibrosis (post-PV MF) or accelerated phase/ blast phase myeloproliferative neoplasm acute myeloid leukemia (AP/BP-MPN AML).
2. Patients with a contraindication to HU according to the SmPC (severe bone marrow depression, leukopenia ($< 2.5 \times 10^9$ leukocytes/L), thrombocytopenia ($< 100 \times 10^9$ platelets/L), severe anemia (< 10 g/dL HGB).
3. Patients with rare hereditary galactose intolerance, total lactase deficiency or glucose-galactose

malabsorption in their past medical history.

4. Active uncontrolled infection that is considered by the Investigator as a reason for exclusion.

5. Active malignancies (except for carcinoma in situ; prostate cancer and breast cancer in remission and - where necessary - ongoing hormonal therapy).

6. Inadequate renal function as demonstrated by Modification of Diet in Renal Disease estimate glomerular filtration rate (MDRDeGFR) ≤ 30 mL/min/1.73m² or on dialysis.

7. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotrophin (hCG) laboratory test.

8. Sexually active males unwilling to use a condom during intercourse while taking study treatment and for at least 3 months after stopping study treatment.

9. HIV patients treated with nucleoside reverse transcriptase inhibitors like didanosine and stavudine.

Other inclusion/exclusion criteria may apply

Germany

Novartis Investigative Site

Recruiting

Erfurt,99085,Germany

Novartis Investigative Site

Recruiting

Guetersloh,33332,Germany

Novartis Investigative Site

Recruiting

Augsburg,86150,Germany

Novartis Investigative Site

Recruiting

Mutlangen,73557,Germany

Novartis Investigative Site

Recruiting

Heidelberg,Baden Wuerttemberg,69115,Germany

Novartis Investigative Site

Recruiting

Gera,07548,Germany

Novartis Investigative Site

Recruiting

Goslar,Niedersachsen,38642,Germany

Novartis Investigative Site

Recruiting

Berlin,10407,Germany

Novartis Investigative Site

Recruiting

Naunhof,04683,Germany

Novartis Investigative Site

Recruiting

Straubing,Bayern,94315,Germany

Novartis Investigative Site

Recruiting

Hannover,30161,Germany

Novartis Investigative Site

Recruiting

Halle Saale,Sachsen-Anhalt,06110,Germany

Novartis Investigative Site

Recruiting

Bonn,53113,Germany

Novartis Investigative Site

Recruiting

Saarbruecken,66113,Germany

Novartis Investigative Site

Recruiting

Langen,Hessen,63225,Germany

Novartis Investigative Site

Recruiting

Kiel,24105,Germany

Novartis Investigative Site

Recruiting

Kronach,Bayern,96317,Germany

Novartis Investigative Site

Recruiting

Donauwoerth,86609,Germany

Novartis Investigative Site

Recruiting

Torgau,04860,Germany

Novartis Investigative Site

Recruiting

Dortmund,Nordrhein-Westfalen,44309,Germany

Novartis Investigative Site

Recruiting

Koeln,50671,Germany

Novartis Investigative Site

Recruiting

Lingen Ems,Niedersachsen,49808,Germany

Novartis Investigative Site

Recruiting

Dresden,01307,Germany

Novartis Investigative Site

Recruiting

Westerstede,26655,Germany

Novartis Investigative Site

Recruiting

Velbert,North Rhine-Westphalia,42551,Germany

Novartis Investigative Site

Recruiting

Merseburg,06217,Germany

Novartis Investigative Site

Recruiting

Koeln,Nordrhein-Westfalen,50674,Germany

Novartis Investigative Site

Recruiting

Erding,85435,Germany

Novartis Investigative Site

Recruiting

Wuerselen,52146,Germany

Novartis Investigative Site

Recruiting

Luebeck,Schleswig-Holstein,23563,Germany

Novartis Investigative Site

Recruiting

Moers,47441,Germany

Novartis Investigative Site

Recruiting

Aachen,North Rhine-Westphalia,52064,Germany

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: +41613241111

Email: novartis.email@novartis.com

Novartis Pharmaceuticals

Phone: 1-888-669-6682

Email: novartis.email@novartis.com

Source URL: *<https://prod1.novartis.com/clinicaltrials/study/nct05853458>*

List of links present in page

1. <https://clinicaltrials.gov/ct2/show/NCT05853458>
2. [#trial-eligibility](#)
3. <tel:+41613241111>
4. <mailto:novartis.email@novartis.com>
5. <tel:1-888-669-6682>
6. <mailto:novartis.email@novartis.com>